The global gene fusion testing market is witnessing strong momentum, underpinned by advancements in genomic technologies and the growing importance of precision oncology. The market was valued at US$ 0.7 billion in 2024 and is projected to reach US$ 2.5 billion by 2035, expanding at a robust CAGR of 12.1% from 2025 to 2035.

Key highlights include:

• The market reached US$ 0.7 billion in 2024
• Expected to climb to US$ 2.5 billion by 2035
• Growth rate projected at 12.1% CAGR
• North America held 38.3% revenue share in 2024
• Next-generation sequencing (NGS) dominated with 42.1% share

This strong growth trajectory reflects increasing integration of molecular diagnostics into routine oncology care.

→Discover Market Opportunities – Request Your Sample Copy Now: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86836

Market Overview

Gene fusion testing has emerged as a cornerstone in cancer diagnostics and treatment planning. It identifies hybrid genes formed by the fusion of two previously separate genes—events that often drive cancer progression in diseases such as lung cancer, leukemia, and sarcomas.

Modern testing approaches include:

• Next-generation sequencing (NGS)
• Fluorescence in situ hybridization (FISH)
• Reverse transcription polymerase chain reaction (RT-PCR)
• Immunohistochemistry (IHC)

These technologies enable oncologists to detect actionable mutations and tailor treatments accordingly. As healthcare shifts toward precision medicine, gene fusion testing is becoming indispensable for improving treatment outcomes, predicting prognosis, and monitoring disease progression.

The growing awareness of cancer genomics, coupled with technological innovation, is accelerating adoption across hospitals, diagnostic labs, and research institutions globally.

Analysts’ Viewpoint

The gene fusion testing market is set for substantial expansion over the next decade. Continuous advancements in genomic technologies and the increasing role of gene fusion events in cancer biology are key growth enablers.

Gene fusions are critical biomarkers for targeted therapies, particularly in cancers such as non-small cell lung cancer and hematological malignancies. The increasing incidence of cancer worldwide, combined with rising demand for personalized treatment approaches, is fueling adoption.

Technologies like NGS and real-time PCR are significantly enhancing detection accuracy, sensitivity, and scalability. As these technologies become more cost-effective and accessible, their integration into clinical workflows will further accelerate market growth.

Key Market Growth Drivers

1. Increasing Incidence of Cancer

The rising global cancer burden is a primary driver of market growth. Aging populations, environmental factors, and lifestyle changes are contributing to higher cancer prevalence.

Gene fusions play a pivotal role in various cancers, including:

• Blood cancers
• Non-small cell lung cancer
• Prostate cancer

Early and accurate detection of these fusions enables targeted therapy selection, improving patient outcomes and survival rates.

2. Rising Demand for Personalized Medicine

Precision oncology is transforming cancer treatment paradigms. Instead of one-size-fits-all therapies, clinicians now rely on genetic insights to customize treatment plans.

Gene fusion testing:

• Identifies actionable mutations
• Enhances treatment efficacy
• Reduces adverse effects

This shift toward individualized care is significantly boosting demand for advanced diagnostic tools.

3. Technological Advancements in Genomics

Innovations in genomic technologies, particularly NGS, have revolutionized gene fusion detection. These advancements offer:

• High-throughput analysis
• Improved sensitivity and specificity
• Faster turnaround times

Declining sequencing costs are also making these technologies more accessible, further driving market expansion.

4. Supportive Regulatory and Reimbursement Frameworks

Government initiatives and favorable reimbursement policies in developed regions are encouraging adoption of molecular diagnostics, including gene fusion testing.

Analysis of Key Players – Key Player Strategies

The global gene fusion testing market is highly competitive, with leading players focusing on innovation, partnerships, and geographic expansion.

Major companies include:

• Amoy Diagnostics Co., Ltd.
• ArcherDX (Integrated DNA Technologies, Inc.)
• Biocartis
• Biocare Medical, LLC
• F. Hoffmann-La Roche Ltd.
• Guardant Health, Inc.
• Illumina, Inc.
• Myriad Genetics, Inc.
• Natera, Inc.
• NeoGenomics, Inc.
• QIAGEN N.V.
• Thermo Fisher Scientific Inc.

Strategic Focus Areas

• Product Innovation: Development of advanced NGS panels and companion diagnostics
• Collaborations: Partnerships with healthcare providers and research institutions
• Geographic Expansion: Strengthening presence in emerging markets such as Asia Pacific
• Regulatory Approvals: Securing FDA and global approvals for diagnostic assays

These strategies are helping companies maintain competitive advantage while expanding their global footprint.

Market Challenges & Opportunities

Challenges

• High Cost of Advanced Testing: NGS-based testing can be expensive, limiting adoption in low-income regions
• Lack of Skilled Professionals: Interpretation of genomic data requires specialized expertise
• Regulatory Complexities: Approval processes for diagnostic tools can be time-consuming
• Limited Awareness in Emerging Markets: Adoption remains uneven across regions

Opportunities

• Expansion in Emerging Economies: Growing healthcare infrastructure in Asia Pacific and Latin America
• Integration with AI and Bioinformatics: Enhancing data interpretation and clinical decision-making
• Companion Diagnostics Growth: Increasing demand for targeted therapies
• Point-of-Care Testing Innovations: Faster and decentralized testing solutions

→Explore Strategies & Trends – Request Full Report Access – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86836

Key Player Strategies

Leading companies are implementing targeted strategies to strengthen market positioning:

• Investment in R&D: Continuous innovation in genomic testing platforms
• Launch of Multi-Gene Panels: Comprehensive solutions for detecting multiple gene fusions simultaneously
• Mergers & Acquisitions: Expanding capabilities and product portfolios
• Focus on Companion Diagnostics: Aligning diagnostics with targeted therapies
• Strengthening Distribution Networks: Enhancing accessibility in untapped markets

These strategies are critical for sustaining growth in a rapidly evolving market landscape.

Recent Developments

• In July 2025, Thermo Fisher Scientific received FDA’s approval for its Oncomine Dx Express Test (on the Ion Torrent Genexus Dx) as a companion diagnostic and tumor-profiling NGS assay, a milestone that also impacts fusion detection workflows.
• In October 2025, Gene Solutions and AMPATH launched a new advanced genomics laboratory in Hyderabad (India) to expand access to NGS-based testing (including oncology/precision medicine, which implicates fusion testing) in the region.
• In September 2024, NeoGenomics, Inc. announced real-world data to be presented at ESMO 2024 showing that testing for 19 drug-targetable gene fusions via NGS identified up to four times more patients eligible for matched therapies compared to tests focusing only on NTRK fusions or using IHC.

Investment Landscape and ROI Outlook

The gene fusion testing market presents a highly attractive investment landscape, driven by strong demand fundamentals and technological innovation.

Investment Highlights

• High CAGR of 12.1% ensures long-term growth potential
• Increasing funding in precision oncology research
• Strong pipeline of diagnostic innovations
• Growing adoption of NGS technologies

ROI Outlook

Investors can expect:

• High returns in emerging markets due to expanding healthcare infrastructure
• Sustained demand from oncology diagnostics
• Opportunities in AI-driven genomics platforms

Venture capital and private equity investments are increasingly flowing into genomics startups, reflecting confidence in the market’s future potential.

Market Segmentations

By Category

• Research
• Diagnostic

By Technology

• Next-Generation Sequencing (NGS)
• Fluorescence In-Situ Hybridization (FISH)
• Polymerase Chain Reaction (PCR)
• Immunohistochemistry (IHC)

NGS leads the segment with a 42.1% market share in 2024, owing to its comprehensive genomic profiling capabilities.

By Indication

• Solid Tumors
• Hematological Malignancies

By End-user

• Pharmaceutical and Biotechnology Companies
• Hospitals and Diagnostic Laboratories
• Academic and Research Centers

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

North America dominates the market with a 38.3% share, supported by advanced healthcare infrastructure, high R&D investments, and strong adoption of personalized medicine.

Asia Pacific is expected to witness the fastest growth due to increasing healthcare investments and rising cancer incidence.

Why Buy This Report?

• Comprehensive analysis of market size, trends, and forecasts up to 2035
• In-depth insights into growth drivers, challenges, and opportunities
• Detailed competitive landscape with key player profiling
• Coverage of advanced technologies such as NGS and PCR
• Regional analysis highlighting growth hotspots
• Strategic recommendations for stakeholders and investors

This report is essential for stakeholders seeking to capitalize on the rapidly evolving gene fusion testing market.

FAQs

1. How big was the global gene fusion testing market in 2024?

The market was valued at US$ 0.7 billion in 2024.

2. What is the projected size of the market by 2035?

It is expected to exceed US$ 2.5 billion by 2035.

3. What are the key drivers of market growth?

The primary drivers include increasing cancer incidence and rising demand for personalized medicine.

4. What is the expected growth rate of the market?

The market is anticipated to grow at a CAGR of 12.1% from 2025 to 2035.

5. Which region dominates the gene fusion testing market?

North America holds the largest share and is expected to maintain its dominance during the forecast period.

Buy Full Report Now: https://www.transparencymarketresearch.com/checkout.php?rep_id=86836&ltype=S

→Explore Latest Research Reports by Transparency Market Research:

Herbal Essentials Market: https://www.transparencymarketresearch.com/herbal-essentials-market.html

Sinus Dilation Devices Market: https://www.transparencymarketresearch.com/sinus-dilation-devices-market.html

Spinal Implants Market: https://www.transparencymarketresearch.com/spinal-implants-market.html

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.